PCM
CRSP icon

Parsons Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Parsons Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,705
Closed -$276K – 426
2021
Q2 		$276K Hold
1,705
– – 0.02% 374
2021
Q1 		$208K Hold
1,705
– – 0.02% 397
2020
Q4 		$261K Sell
1,705
-1,395
-45% -$165K 0.02% 337
2020
Q3 		$259K Hold
3,100
– – 0.03% 310
2020
Q2 		$228K Buy
+3,100
New +$181K 0.02% 313
2018
Q3 		– Sell
-4,130
Closed -$243K – 359
2018
Q2 		$243K Buy
+4,130
New +$235K 0.03% 326

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Parsons Capital Management's CRSP Position: Q3 2021 in Review

Parsons Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,705 shares — an estimated $276K sold.

Parsons Capital Management first reported a position in CRSP in Q2 2018 and held it in 6 quarters. The position peaked at $276K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Parsons Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parsons Capital Management sold 1,705 CRISPR Therapeutics shares in Q3 2021, an estimated $276K.
  • Parsons Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 6 quarters.
  • Parsons Capital Management's CRISPR Therapeutics position peaked at $276K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Parsons Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.